ArticleBlood advances2026
The role of HLA transcription in unrelated hematopoietic cell transplantation.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractExpression levels of HLA are associated with susceptibility to various diseases and outcomes after allogeneic hematopoietic cell transplantation (HCT). However, there has been no comprehensive analysis of the effect of the expression levels of the HLA-A, -B, -C, and -DRB1 alleles in unrelated HCT (UR-HCT). Using the capture RNA-sequencing method, we analyzed the gene expression of HLA alleles in 443 healthy donors and determined allele-specific transcription (AST) levels. We assigned median AST (M-AST) levels to HLA typing data of patients who received a transplant from unrelated donors matched for HLA-A, -B, -C, and -DRB1 alleles, using transplant registry data. All 6084 patients were divided into low, middle, and high tertile groups according to the distribution of the sum of the 2 alleles of the M-AST level for each HLA locus and the sum of the 8 alleles of the M-AST level for all 4 loci. The risk of grade 2 to 4 acute graft-versus-host disease was significantly higher in the middle group (hazard ratio [HR], 1.11; P = .044) and high group (HR, 1.20; P< .001) than in the low group for the sum of the HLA-A, -B, -C, and -DRB1 loci. Similar results were observed at the HLA-A, -B, -C, and -DRB1 loci. Higher transcription levels were also associated with a lower risk of relapse at the HLA-B, -C, and -DRB1 loci. Our data suggest that high transcription levels of patient and/or donor HLA may evoke strong alloimmune responses and affect UR-HCT outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.